Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous CIK cells in advanced sarcoma
NCT04802070Phase 1Completed
- Start
- Jan 2021
- Primary completion
- Mar 2023
- Modality
- Prophylactic Vaccines, Allogeneic CAR-T, Tumor-Infiltrating Lymphocytes (TILs)
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of autologous cytokine-induced killer cells in sarcoma. Primary endpoint: Dose Limiting Toxicity at 6 weeks. Started Jan 2021; status: completed.
02
Drugs
autologous cytokine-induced killer cells
03
Conditions
sarcoma
Beyond the preview
Go deeper on NCT04802070.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04802070.